3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Withdrawn
1
Sponsor Class
OTHER_GOV
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Opportunistic Infections
1
Inflammation
1
Epstein-Barr Virus Infections
1
Cytomegalovirus Infections
1
Coinfection
1
Acquired Immunodeficiency Syndrome
1
Interventions
Cisplatin
48
Capecitabine
41
Gemcitabine
33
apatinib
32
Oxaliplatin
32
Cyclophosphamide
31
Radiotherapy
29
Paclitaxel
29
Carboplatin
29
tislelizumab
27
Irinotecan
27
Drug Therapy
27
Fluorouracil
26
Docetaxel
26
Bevacizumab
23
fludarabine
18
Nivolumab
17
pembrolizumab
16
Surgical Procedures, Operative
16
Exercise
16
Metformin
15
S 1 (combination)
14
camrelizumab
13
Radiation
13
Pemetrexed
13
Control Groups
12
anlotinib
11
Leucovorin
11
Vinorelbine
10
Standard of Care
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER_GOV
×
Interventional
×
Nucleosides
×
Clear all
NCT04183738
2020-11-10
i2-D²EFT
Kirby Institute
Phase 4
Withdrawn